Work

The emerging role of microRNAs in drug responses.

Year: 2010

Type: review

Abstract: In recent years, pharmacogenomic research has begun to integrate genetics, gene expression and pharmacological phenotypes. MicroRNAs (miRNAs), 21- to 25-nucleotide, non-coding RNAs that are present in almost all metazoan genomes, are a class of gene regulators that downregulate gene expression at the post-transcriptional level. Experimental evidence for the role of miRNAs in regulating pharmacology-related genes and drug responses is increasing. Given the universal roles of miRNAs in various diseases, including cancer, miRNAs (eg, chemotherapy) are anticipated to have potential therapeutic effects in various diseases. The incorporation of miRNAs into pharmacogenomic research could provide improved insight into drug responses. However, more studies are necessary to evaluate the effects of these molecules in patients.

Source: PubMed

Authors: Wei Zhang, M Eileen Dolan

Institution: University of Chicago

Language: English

Topic: MicroRNA in disease regulation

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Cancer Institute, National Institute of General Medical Sciences

Awards: Incorporation of microRNA expression in pharmacogenetic prediction models, Genetic determinants associated with pemetrexed response and toxicity, PAAR-Pharmacogenomics of Anticancer Agents Research Group, SPORE in Breast Cancer